VANGUARD was presented at the 29th International Congress of The Transplantation Society (TTS 2022) which was held in Buenos Aires from 10-14 September 2022. The abstract for the VANGUARD presentation titled Generation of Prevascularized Endocrine Constructs to Treat Type 1
A new VANGUARD publication has recently been made available in Transplant International. Its name is “Ethics of Early Clinical Trials of Bio-Artificial Organs” and the publication outlines the ethical challenges addressed by Erasmus University Medical Center Rotterdam team. Although the
A new VANGUARD article has recently been published in Current Opinion in Endocrine and Metabolic Research. “Advances and challenges of endocrine pancreas bioengineering” – Islet transplantation is a valid treatment option for type 1 diabetes patients. Despite the advantages of
On June 3-4, the VANGUARD consortium finally met in person after two years of online meetings. The meeting, which took place at the Geneva University Hospital, was an important occasion to discuss the progress of the project and present the
Bio-artificial organs and bio-engineered or bio-printed tissues for transplantation in humans are rapidly being developed. It is anticipated that some applications will be ready for clinical testing in the near future. How can first-in-human clinical trials be conducted in a
The VANGUARD consortium recently published collaborative work in the journal Transplant International on the generation of pre-vascularised organoids. The authors from the University of Geneva and the University of Eastern Piedmont show that pre-vascularized islet organoids exhibit enhanced in vitro
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 874700